Monte Rosa Therapeutics, Inc. Common Stock
GLUEStock
$23.16+346.01%52W
Market Cap$1.98B
P/E—
Div yield—
Beta1.48
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)37.86%
Price vs S&P 500 (4W)29.87%
VGM Score39.88
Market Capitalization$1.98B
Earnings Surprise History
Q1 26-0.45est. -0.39
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.27
4.27
4.27
4.27
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GLUEMonte Rosa Therapeutics, Inc. Common Stock | D | F | A | $23.16 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Monte Rosa Therapeutics develops molecular glue degraders (MGDs), a novel class of small molecules designed to selectively degrade disease-relevant proteins by harnessing the body's natural protein destruction mechanisms. Leveraging its proprietary QuEEN platform and AI-driven discovery, the company has assembled a library of over 50,000 MGD candidates. Its lead program, MRT-2359, targets GSPT1 in MYC-driven tumors.